BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 36283501)

  • 1. The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer.
    Balla A; Bhak J; BirĂ³ O
    Mol Cell Probes; 2022 Dec; 66():101871. PubMed ID: 36283501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation.
    Gao Y; Zhou N; Liu J
    Cancer Control; 2024; 31():10732748241255548. PubMed ID: 38764160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy: current technology and clinical applications.
    Nikanjam M; Kato S; Kurzrock R
    J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.
    Giannopoulou L; Kasimir-Bauer S; Lianidou ES
    Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
    Cheng X; Zhang L; Chen Y; Qing C
    J Ovarian Res; 2017 Nov; 10(1):75. PubMed ID: 29132396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy in ovarian cancer.
    Giannopoulou L; Lianidou ES
    Adv Clin Chem; 2020; 97():13-71. PubMed ID: 32448432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
    Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
    Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells as a "real-time liquid biopsy": Recent advances and the application in ovarian cancer.
    Jou HJ; Ling PY; Hsu HT
    Taiwan J Obstet Gynecol; 2022 Jan; 61(1):34-39. PubMed ID: 35181043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in liquid biopsy-based markers in NSCLC.
    Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q
    Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential clinical utility of liquid biopsies in ovarian cancer.
    Zhu JW; Charkhchi P; Akbari MR
    Mol Cancer; 2022 May; 21(1):114. PubMed ID: 35545786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
    Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer.
    Gahlawat AW; Witte T; Sinn P; Schott S
    Sci Rep; 2023 Apr; 13(1):5503. PubMed ID: 37015943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
    Zhang X; Ju S; Wang X; Cong H
    Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
    Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
    Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies.
    Jiang P; Chan KCA; Lo YMD
    J Hepatol; 2019 Aug; 71(2):409-421. PubMed ID: 31004682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The functional and clinical roles of liquid biopsy in patient-derived models.
    Zhu Z; Hu E; Shen H; Tan J; Zeng S
    J Hematol Oncol; 2023 Apr; 16(1):36. PubMed ID: 37031172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis.
    Morrison G; Buckley J; Ostrow D; Varghese B; Cen SY; Werbin J; Ericson N; Cunha A; Lu YT; George T; Smith J; Quinn D; Duddalwar V; Triche T; Goldkorn A
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers.
    Zhang Z; Wu H; Chong W; Shang L; Jing C; Li L
    Cell Death Dis; 2022 Oct; 13(10):903. PubMed ID: 36302755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.